Related Experiment Video
Updated: Aug 10, 2025
Minimally Invasive Cisterna Magna Injection Model for Leptomeningeal Metastasis Studies in Mice
Published on: May 23, 2025
Comparative Efficacy of ALK Inhibitors for Treatment-Naïve ALK-Positive Advanced Non-Small Cell Lung Cancer with
Koichi Ando1,2, Ryo Manabe1, Yasunari Kishino1
1Division of Respirology and Allergology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan.
Abstract:
Central nervous system (CNS) metastases and acquired resistance complicate the treatment of anaplastic lymphoma kinase (ALK) rearrangement-positive (ALK-p) advanced non-small cell lung cancer (NSCLC). Thus, this review aimed to provide a comprehensive overview of brain metastasis, acquired resistance, and prospects for overcoming these challenges. A network meta-analysis of relevant phase III randomized controlled trials was performed to compare the efficacies of multiple ALK inhibitors by drug and generation in overall patients with ALK-p untreated advanced NSCLC and a subgroup of patients with CNS metastases. The primary endpoint was progression-free survival (PFS). Generation-specific comparison results showed that third-generation ALK inhibitors were significantly more effective than second-generation ALK inhibitors in prolonging the PFS of the subgroup of patients with CNS metastases. Drug-specific comparison results demonstrated that lorlatinib was the most effective in prolonging PFS, followed by brigatinib, alectinib, ensartinib, ceritinib, crizotinib, and chemotherapy. While lorlatinib was superior to brigatinib for PFS in the overall patient population, no significant difference between the two was found in the subgroup of patients with CNS metastases. These results can serve as a foundation for basic, clinical, and translational research and guide clinical oncologists in developing individualized treatment strategies for patients with ALK-p, ALK inhibitor-naive advanced NSCLC.
Insights
Third-generation anaplastic lymphoma kinase (ALK) inhibitors improve progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) with brain metastases. Lorlatinib showed the highest efficacy, guiding personalized treatment strategies for ALK-positive NSCLC.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Anaplastic lymphoma kinase (ALK) rearrangement-positive (ALK-p) advanced non-small cell lung cancer (NSCLC) presents treatment challenges due to central nervous system (CNS) metastases and acquired resistance.
- Effective therapeutic strategies are needed to overcome these complications and improve patient outcomes.
Purpose of the Study:
- To provide a comprehensive overview of brain metastasis and acquired resistance in ALK-p advanced NSCLC.
- To compare the efficacy of various ALK inhibitors in patients with and without CNS metastases using a network meta-analysis.
Main Methods:
- A network meta-analysis of Phase III randomized controlled trials was conducted.
- Efficacy of multiple ALK inhibitors (by drug and generation) was compared for progression-free survival (PFS).
- Analyses included both overall ALK-p advanced NSCLC patients and a subgroup with CNS metastases.
Main Results:
- Third-generation ALK inhibitors demonstrated significantly better PFS than second-generation inhibitors in the CNS metastases subgroup.
- Lorlatinib exhibited the highest efficacy in prolonging PFS, followed by brigatinib, alectinib, ensartinib, ceritinib, crizotinib, and chemotherapy.
- Lorlatinib showed superior PFS over brigatinib in the overall population, but not in the CNS subgroup.
Conclusions:
- Third-generation ALK inhibitors represent a significant advancement for ALK-p advanced NSCLC patients with CNS metastases.
- Lorlatinib is a highly effective treatment option, particularly for patients with brain involvement.
- Findings support individualized treatment strategies for ALK-p advanced NSCLC, guiding clinical oncologists and future research.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...